Corient Private Wealth LLC Reduces Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Corient Private Wealth LLC decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,009 shares of the company's stock after selling 4,678 shares during the quarter. Corient Private Wealth LLC owned about 0.15% of Krystal Biotech worth $6,738,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech in the 3rd quarter worth approximately $40,000. KBC Group NV grew its position in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company's stock worth $117,000 after buying an additional 132 shares in the last quarter. Avanza Fonder AB bought a new position in Krystal Biotech in the 4th quarter worth about $119,000. Blue Trust Inc. increased its stake in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after acquiring an additional 433 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after acquiring an additional 82 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on KRYS. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $220.00.

Remove Ads

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded down $2.14 during midday trading on Tuesday, hitting $192.30. 279,163 shares of the company traded hands, compared to its average volume of 284,097. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The stock has a 50-day moving average price of $167.55 and a 200 day moving average price of $173.62. The firm has a market cap of $5.54 billion, a P/E ratio of 64.31 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the prior year, the company earned $0.30 EPS. The business's revenue was up 116.4% compared to the same quarter last year. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).